Logo

Roche's Elecsys Anti-SARS-CoV-2 S Receives the US FDA's EUA to Detect Ab Against SARS-CoV-2 Spike Protein

Share this

Roche's Elecsys Anti-SARS-CoV-2 S Receives the US FDA's EUA to Detect Ab Against SARS-CoV-2 Spike Protein

Shots:

  • The US FDA’s EUA follows the launch of the Elecsys Anti-SARS-CoV-2 S Ab test for markets accepting the CE Mark. The serology test can be used to measure the level of Abs in people who have been exposed to the SARS-CoV-2 virus
  • The test has both a high NPA of 99.98% and PPA of 96.6%- 15days or later after diagnosis with a PCR test. The test may help identify recovering patients who could potentially be serum & plasma donors for developing treatments for COVID-19
  • The test runs on Roche’s cobas e analyzers and is the latest addition to Roche’s diagnostic portfolio to help healthcare systems combat COVID-19 through testing in the laboratory and at the POC

 ­ Ref: Roche | Image: Roche 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions